Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, leading health-care company, Humana Inc. (HUM - Analyst Report) joined hands with the global pharmaceutical company, Eli Lilly and Company (LLY - Analyst Report) to form a research collaboration that will provide cost effective and improved healthcare outcomes.

Kentucky based Humana provides a wide range of insurance products, and health and wellness services. On the other hand, Eli Lilly utilizes modern research to address the world’s medical exigencies. The partnership will utilize these areas of expertise of both the companies to optimize the quality of patient care by researching on various diseases. Humana and Eli Lilly will conduct a number of studies. The initial phase of the studies will include investigation of patient characteristics associated with rising health care costs for type2 diabetic patients.

Recently, healthcare costs have increased tremendously. Since 1980, U.S. health expenditures have increased more than ten times and are expected to grow faster than national income in the foreseeable future, as per sources. However, the quality of healthcare has not shown as much improvement as compared to the escalating costs. Thus both the companies, each being esteemed players in their respective markets, decided to form an alliance to address this issue and come up with a solution.
    
As per sources, more than one sixth of the country’s expenditures are devoted to healthcare spending. But a huge part of it is spent every year over inefficient and wasteful health care. Many healthcare companies at present are struggling to provide improved patient care at affordable rates. But we believe the strategic alliance with Eli Lilly will position Humana to take an upper hand in this regard and cater to the growing healthcare industry successfully.

Humana currently carries a Zacks Rank #3 (Hold). Among other health service companies, Aetna Inc. (AET - Analyst Report) and Centene Corp. (CNC - Snapshot Report) carry a Zacks Rank #2 (Buy) and appear impressive.




 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 34.08 +10.76%
NOAH HOLDING NOAH 14.01 +5.42%
DIXIE GROUP DXYN 14.68 +4.41%
VALEO SA SPO VLEEY 68.09 +4.22%
CANADIAN SOL CSIQ 26.13 +3.79%